The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells

Autor: Sébastien Anguille, Herman Goossens, Johan M.J. Van den Bergh, Tessa Kerre, Zwi N. Berneman, Marc Peeters, Evelien Smits, Carlo Heirman, Viggo Van Tendeloo, Sarah Bonte, Kris Thielemans, Barbara Stein, Yannick Willemen
Přispěvatelé: Laboratory of Molecullar and Cellular Therapy, Immunology and Microbiology, Vriendenkring VUB, Physiology, Basic (bio-) Medical Sciences, Immunomodulation in Chronic Inflammatory Diseases, Faculty of Psychology and Educational Sciences
Rok vydání: 2016
Předmět:
0301 basic medicine
CHRONIC
T-Lymphocytes
medicine.medical_treatment
Gene Expression
COLORECTAL-CANCER
Cancer immunotherapy
Neoplasms
Medicine and Health Sciences
Receptor
IN-VIVO
MYELODYSPLASTIC SYNDROME
LYMPHOCYTIC-LEUKEMIA
Antigen Presentation
Extracellular Matrix Proteins
hyaluronan-mediated motility receptor
messenger RNA
Electroporation
Myeloid leukemia
Hyaluronan-mediated motility receptor
Leukemia
Myeloid
Acute
Hyaluronan Receptors
Oncology
immunotherapy
MESSENGER-RNA
Research Paper
electroporation
ACUTE MYELOID-LEUKEMIA
Cancer Vaccines
03 medical and health sciences
Immune system
Antigen
Antigens
Neoplasm
MULTIPLE-MYELOMA
medicine
Humans
HYALURONAN-MEDIATED MOTILITY
RNA
Messenger
Biology
RECEPTOR
HLA-A Antigens
business.industry
Biology and Life Sciences
Dendritic Cells
Immunotherapy
vaccination
030104 developmental biology
Immunology
Human medicine
business
PEPTIDE VACCINATION
Zdroj: Oncotarget
ONCOTARGET
ISSN: 1949-2553
DOI: 10.18632/oncotarget.12170
Popis: We formerly demonstrated that vaccination with Wilms tumor 1 (WT1)-loaded autologous monocyte-derived dendritic cells (mo-DCs) can be a well-tolerated effective treatment in acute myeloid leukemia (AML) patients. Here, we investigated whether we could introduce the receptor for hyaluronic acid-mediated motility (RHAMM/HMMR/CD168), another clinically relevant tumor-associated antigen, into these mo-DCs through mRNA electroporation and elicit RHAMM-specific immune responses. While RHAMM mRNA electroporation significantly increased RHAMM protein expression by mo-DCs, our data indicate that classical mo-DCs already express and present RHAMM at sufficient levels to activate RHAMM-specific T cells, regardless of electroporation. Moreover, we found that RHAMM-specific T cells are present at vaccination sites in AML patients. Our findings implicate that we and others who are using classical mo-DCs for cancer immunotherapy are already vaccinating against RHAMM.
Databáze: OpenAIRE
Externí odkaz: